Description

The TCR Activator/PD-L2 Mammalian Expression Kit is designed for the creation of engineered cells expressing TCR Activator and PD-L2. The kit consists of transfection-ready vectors encoding TCR activator and human PD-L2 that can be used to transfect cells and create target cells that overexpress PD-L2 and an engineered cell surface T cell receptor (TCR) activator. The kit contains enough plasmids for 500 assays if using a 96-well plate. TCR Activator expression vector alone is also provided as control for cellular experiments involving PD-L2.



Figure 1: Illustration of the principle of a PD-1:PD-L1/PD-L2 cellular assay.
Jurkat T cells expressing NFAT reporter with constitutive expression of PD-1 (PD-1/NFAT Reporter Jurkat Cell Line, BPS Bioscience #60535) act as effector cells. When co-cultivated, TCR complexes on PD-1/NFAT Reporter Jurkat cells are activated by the TCR activator expressed in the transfected cell line of interest, resulting in expression of the NFAT luciferase reporter. However, PD-1 and PD-L1/PD-L2 ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti- PD-1 or anti- PD-L1/PD-L2 antibodies. Neutralizing antibodies block PD-1:PD-L1/PD-L2 interaction and result in reactivation of the NFAT responsive luciferase reporter.

Note: For assays in more difficult to transfect cell types, we suggest using our lentiviral products. The corresponding lentiviral product for this kit is BPS Bioscience #79894.

Background

PD-L1 and PD-L2 binding to PD-1, a receptor expressed on T-cells, negatively regulates immune responses. PD-1 ligands PD-L1 and PD-L2 are found on the surface of many cancer cells, and their interaction with receptor PD-1 inhibits T cell activity and allows cancer cells to escape immune surveillance. This pathway is also involved in regulating autoimmune responses. Therefore, these proteins (termed immune checkpoints) are promising therapeutic targets for many types of cancer as well as multiple sclerosis, arthritis, lupus, and type I diabetes. Checkpoint inhibitors have remarkable efficacy in a wide range of cancer types and have revolutionized cancer treatment. PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab and PD-L1 inhibitors atezolizumab, avelumab, and durvalumab are all FDA-approved drugs for immuno-therapy.

Application

- Screen for compound activity on of PD-1 or PD-L1/PD-L2 signaling in a cellular model.
- Characterize the biological activity of PD-1 and its interactions with PD-L2.

Supplied Materials

Catalog #	Name	Amount	Storage
	TCR Activator + Human PD-L2 (expression vectors for expressing TCR Activator and human PD-L1) (100 ng/µl)	500 µl	-20°C
	TCR Activator (expression vectors for expressing TCR Activator) (100 ng/µl)	500 µl	-20°C

Materials Required but Not Supplied

Name	Ordering Information
Cell line of interest, such as HEK293 cells, and corresponding culture media	
Transfection Reagent, such as Lipofectamine™ 2000 Transfection Reagent	Thermo Fisher #11668027
Opti-MEM I reduced Serum Medium	Thermo Fisher #31985-062
PD-1/NFAT Reporter Jurkat Cell Line	BPS Bioscience #60535
Anti-PD-1 Neutralizing Antibody	BPS Bioscience #71120
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
White clear-bottom 96-well cell culture plate	
Luminometer	

Assay Medium:
RPMI1640 + 10% FBS + 1% Penicillin/Streptomycin.

Storage Conditions

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed.

Assay Protocol

- The following assays are designed for 96-well format. To perform the assay in different tissue culture formats, the cell number and reagent volumes should be scaled appropriately.
- The protocol described is designed for HEK293 as cells of interest. The use of other cells may require optimization.
- The transfection protocol is a general guideline using Lipofectamine™ 2000 and we recommend referring to the manufacturer's instructions for updated and detailed information.
- The experiments should be performed in triplicate.
- The assay should include "Cell-Free Control", "Unstimulated Control" and "Test Condition" wells.

A. Effect of anti-PD-1 Antibody on PD-1: PD-L2 binding.

Day 1:

1. Seed HEK293 cells, at a density of ~35,000 cells in 100 µl/well of appropriate cell culture media into a white clear-bottom 96-well cell culture plate. Leave some wells with only assay medium for background determination.

   Note: This cell density should result in HEK293 being 90% confluent the next day.

2. Incubate cells at 37°C with 5% CO_2 overnight.

Day 2:

3. Transfect each well with 1 µl of TCR Activator + Human PD-L2, following the transfection reagent's manufacturer's protocol. The protocol described below is a guideline only for use of Lipofectamine™ 2000 and may require optimization to obtain the appropriate transfection efficiency and low cell toxicity.

   a. Mix 1 µl of DNA with 15 µl of antibiotic-free Opti-MEM I Reduced Serum Medium.

   b. Prepare a mix of 0.3 µl of Lipofectamine ™ 2000 with 15 µl of Opti-MEM I Reduced Serum Medium for each reaction.

   c. Incubate for 5 minutes at Room Temperature (RT).

   d. Combine the diluted DNA with diluted Lipofectamine™ 2000 (15 µl + 15 µl).

   e. Mix gently and incubate for 25 minutes at RT.

   f. Add DNA/Lipofectamine™ 2000 mix to cells (30 µl/well).

   g. Incubate cells at 37°C in a CO2 incubator for 6-24 hours.

   h. Gently remove spent media and replenish with fresh media.

   i. Visualize cells under a microscope for signs of cell toxicity. If needed, allow cells to recover for an extra 24 hours.

Day 3:

4. Prepare a serial dilution of the anti-PD-1 antibody at 2x the desired final concentration in assay medium (25 µl/well).

5. Pre-incubate PD-1/NFAT Reporter Jurkat cells with the diluted anti-PD-1 antibody (1:1 volume ratio) for 30 minutes (50 µl of mix/well).

6. Remove media carefully from the transfected HEK293-containing wells.

7. Add 50 µl of fresh assay medium to the wells containing the transfected HEK293 cells.

8. Add the mixture of Jurkat cells/antibody to the transfected HEK293 cells (50 µl/well).

9. Add 100 µl of assay medium to the "Unstimulated Control" and "Cell-Free Control" wells (for determining the background luminescence).

10. Incubate the cells at 37°C in a CO_2 incubator for 16 hours.

11. Add 100 µl of ONE-Step™ Luciferase Assay reagent to all wells.

12. Rock at room temperature for ~30 minutes.

13. Measure luminescence using a luminometer.

14. Data Analysis: Subtract the average background luminescence (cell-free control wells) from the luminescence reading of all wells. The fold induction of luciferase activity is the background-subtracted luminescence of stimulated cells divided by the average background-subtracted luminescence of unstimulated control wells.

$$Fold\ induction = \frac{Lumin.\ stimulated\ cells - ave.\ background}{Lumin.\ unstimulated\ cells - ave.\ background}$$

Validation Data



Figure 2. Response of HEK293 cells transfected with TCR Activator and human PD-L2 to anti-PD-1 antibody.
HEK293 cells were transiently transfected with human PD-L2 and TCR Activator. The next day, PD-1/NFAT Reporter Jurkat cells were pre-incubated with the Anti-PD-1 Neutralizing Antibody for 30 minutes prior to co-culture with transfected HEK293 cells. After ~16 hours NFAT activity was measured using ONE-Step™ Luciferase. The fold induction is equal to background-subtracted luminescence of antibody-treated well/background-subtracted luminescence of untreated-control wells.



Figure 3. Dose response curve of HEK293 cells transfected with TCR Activator and human PD-L2 to anti-PD-1 antibody.
HEK293 cells were transiently transfected with human PD-L2 and TCR Activator. The next day, PD-1/NFAT Reporter Jurkat cells were pre-incubated with the increasing amounts of Anti-PD-1 Neutralizing Antibody for 30 minutes prior to co-culture with transfected HEK293 cells. After ~16 hours NFAT activity was measured using ONE-Step™ Luciferase. The fold induction is equal to background-subtracted luminescence of antibody-treated well/background-subtracted luminescence of untreated-control wells. The fold induction is equal to background-subtracted luminescence of antibody-treated well/background-subtracted luminescence of untreated-control wells.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

References
Sasca D, et al. (2019) Blood 133: 2305-2319.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.

Related Products

Products	*Catalog #*	*Size*
NFAT Luciferase Reporter Jurkat Cell Line	60621	2 vials
PD-L1 /TCR Activator CHO Cell Line	60536	2 vials
TCR Activator CHO Cell Line	60539	2 vials
Anti-PD-L1 (CD274) Neutralizing Antibody	71213	100 µg
PD1:PD-L1/PD-L2 Cell-Nased Inhibitor Screening Assay Kit	60800	96 reactions

Version 031924